None
Conditions
Interventions
Experimental group:Oral administration: Sea eel collagen peptide (600 mg per dose, once daily, taken 2 hours after breakfast, for 28 consecutive days)
Sponsors
Shanghai Fengxian District Central Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Aged 30–50 years, including at least 15 participants aged 30–40 years and at least 15 participants aged 41–50 years; in good general health, willing to participate in the study voluntarily and having signed written informed consent; 2.Relatively stable skin condition, with no clinically significant inflammation, allergic reactions, or severe infections; 3.No obvious scars, nevi, extensive telangiectasia, or other skin markings in the facial test areas (forehead or bilateral cheeks) that may interfere with outcome assessment; 4.Able to comply with the study protocol, including regular follow-up visits, proper use of study products as required, and cooperation with standardized photographic documentation; 5.No participation in any other clinical studies involving the test areas within the past 2 months, and no concurrent participation in similar studies during the trial period.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women, or those planning to become pregnant in the near future; 2.Individuals with high sensitivity constitution, or a history of drug allergy, food allergy, severe cosmetic allergy, metal allergy, dermatological diseases, or relevant medical history; 3.Participants who have received topical or systemic treatments that may affect the tolerability of the investigational product within one week prior to study initiation; 4.Individuals with pathological signs or extensive skin features in the test area, including but not limited to birthmarks, scratches, leukoderma, pigmented nevi, scars, or other conditions that may interfere with study evaluations; 5.Participants who have participated in other clinical trials within the past 2 months, or who are deemed unsuitable for this study based on clinical assessment by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sebum content (Sebum);Skin erythema (redness index) and erythematous area proportion;Facial imaging parameters;;Skin moisture content (skin hydration);Transepidermal water loss (TEWL);; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety-related laboratory parameters, including liver and renal function;Subject self-assessment questionnaire (perceived moisturization, comfort, skin quality changes, and satisfaction);;Adverse event recording; | — |
Countries
China
Contacts
Public ContactMan Wang
Shanghai Fengxian District Central Hospital
Outcome results
None listed